ONSTRIDE-1: A Phase 3, Randomized, Double-blind, Placebo-Controlled, Efficacy and Safety Study of HBS-301 in Participants with Narcolepsy Followed by an Open-label Extension

Illuminate Brain Fog

Wake Up Narcolepsy 2026 National Summit Recap

Institute for Clinical and Economic Review Releases Evidence Report on Treatment for Narcolepsy

Now enrolling: Brilliance clinical studies for narcolepsy

Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting

2026 Narcolepsy Family Weekend Recap

Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2

Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders

A Beginner’s Guide to Managing Heart Health and Narcolepsy